Presidio Medical, Inc. is focused on developing a groundbreaking neuromodulation platform aimed at treating conditions associated with undesired neural activity, particularly chronic pain. Their innovative technology, known as Ultra Low Frequency (ULF™) neuromodulation, operates by inhibiting pain signals through a unique mechanism that involves the inactivation of sodium channels in pain neurons. This approach is distinct from traditional spinal cord stimulation (SCS) technologies, which typically activate neurons. In clinical trials, ULF™ neuromodulation has demonstrated significant efficacy, with a high percentage of patients reporting substantial pain relief without the side effects commonly associated with other pain management therapies, such as paresthesia.

The company is currently in the clinical stage of development, emphasizing the need for more effective treatments for chronic pain, which affects millions of individuals in the U.S. alone. Presidio Medical's commitment to advancing neuromodulation therapies is underscored by their focus on scientific research and clinical validation, as evidenced by their publications in reputable medical journals. Their approach not only aims to provide relief for patients suffering from chronic pain but also seeks to address the broader public health challenge posed by opioid prescriptions and their associated risks.

United States

We are a clinical-stage, privately held medical technology company developing a transformational neuromodulation platform to treat diseases of undesired neural activity.

Presidio Medical, Inc.

Company Details